跳至主要内容
临床试验/2023-509431-29-00
2023-509431-29-00招募中2 期

Treatment with Risedronate for dilated cardiomyopathy due to Troponin T alteration due to K210 deletion.

Fundacion Para La Formacion E Investigacion Sanitaria De La Region De Murcia1 个研究点 分布在 1 个国家目标入组 5 人开始时间: 2024年8月26日最近更新:
适应症

试验速览

阶段
2 期
状态
招募中
发起方
入组人数
5
试验地点
1
主要终点
Change in LVEF, measured by echocardiography, at 6 months.

研究概览

简要总结

To study whether the administration of Risedronate 10 mg/day in patients with dilated cardiomyopathy due to K210 deletion mutation in the Troponin T gene is associated with: A change in left ventricular function, measured by Echocardiogram

入排标准

年龄范围
18 years 至 65+ years(18-64 Years, 65+ Years)
接受健康志愿者

入选标准

  • Older than 18 years old
  • Dilated cardiomyopathy due to K210 deletion mutation in the Troponin T gene
  • Patients who have given written informed consent

排除标准

  • Hypersensitivity to Risedronate
  • Hypocalcemia
  • Severe renal failure (eGFR < 30 ml/min/1.73m2)
  • History of esophageal disorders, with delay in transit or esophageal emptying, due to example, stenosis or achalasia
  • Barrett's esophagus
  • Inability to remain upright for at least 30 minutes after taking of the tablet.
  • Active treatment with corticosteroids or chemotherapy
  • Pregnant or breastfeeding women
  • Use of other investigational drugs at the time of inclusion, or during the 30 days prior to inclusion

结局指标

主要结局

Change in LVEF, measured by echocardiography, at 6 months.

Change in LVEF, measured by echocardiography, at 6 months.

次要结局

  • Improvement in functional capacity, measured in the stress test with oxygen consumption, at 6 months.

研究者

发起方
Fundacion Para La Formacion E Investigacion Sanitaria De La Region De Murcia
申办方类型
Educational Institution
责任方
Principal Investigator
主要研究者

María Muñoz García

Scientific

Fundacion Para La Formacion E Investigacion Sanitaria De La Region De Murcia

研究点 (1)

Loading locations...

相似试验